Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach
The purpose of the study is to see how effective the combination of chemotherapy drugs
VP-16, chlorambucil, dexamethasone, and vincristine is for patients who have blood cancers
that have returned or not responded to prior treatment. Some patients may also receive a
medication called rituximab if their doctor thinks it is appropriate. This drug combination
will be given to study participants in a low dose continuous basis. The study will also
collect information about the side effects of the above drug combination on patients with
these types of cancers. Previous studies on patients with non-Hodgkin's lymphoma indicate
that some patients treated with this drug combination achieved a high response. The aim of
this study is to test this drug combination in a controlled setting.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Either complete or partial remission, or stabilization of disease pending complete recovery of non hematologic toxicity (aside from alopecia), with return of blood cell counts to > 1000 granulocytes and > 50,000 platelets.
Progressive disease during therapy after 2 cycles.
D Quintana, MD
UNM Cancer Center
United States: Institutional Review Board
|University of New Mexico Cancer Center||Albuquerque, New Mexico 87131-5636|